- Home
- FULC vs DRTS Comparison
FULC vs DRTS Comparison
Compare FULC & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FULC
- DRTS
- Stock Information
- Founded
- FULC 2015
- DRTS 2015
- Country
- FULC United States
- DRTS Israel
- Employees
- FULC N/A
- DRTS N/A
- Industry
- FULC Biotechnology: Pharmaceutical Preparations
- DRTS Medical/Dental Instruments
- Sector
- FULC Health Care
- DRTS Health Care
- Exchange
- FULC Nasdaq
- DRTS Nasdaq
- Market Cap
- FULC 372.2M
- DRTS 300.2M
- IPO Year
- FULC 2019
- DRTS N/A
- Fundamental
- Price
- FULC $7.44
- DRTS $3.86
- Analyst Decision
- FULC Buy
- DRTS Strong Buy
- Analyst Count
- FULC 8
- DRTS 1
- Target Price
- FULC $7.13
- DRTS $9.00
- AVG Volume (30 Days)
- FULC 398.4K
- DRTS 63.7K
- Earning Date
- FULC 11-12-2025
- DRTS 08-11-2025
- Dividend Yield
- FULC N/A
- DRTS N/A
- EPS Growth
- FULC N/A
- DRTS N/A
- EPS
- FULC N/A
- DRTS N/A
- Revenue
- FULC N/A
- DRTS N/A
- Revenue This Year
- FULC N/A
- DRTS N/A
- Revenue Next Year
- FULC N/A
- DRTS N/A
- P/E Ratio
- FULC N/A
- DRTS N/A
- Revenue Growth
- FULC 2752.05
- DRTS N/A
- 52 Week Low
- FULC $2.32
- DRTS $2.11
- 52 Week High
- FULC $8.50
- DRTS $4.39
- Technical
- Relative Strength Index (RSI)
- FULC 59.83
- DRTS 66.76
- Support Level
- FULC $6.69
- DRTS $3.80
- Resistance Level
- FULC $7.50
- DRTS $3.94
- Average True Range (ATR)
- FULC 0.40
- DRTS 0.17
- MACD
- FULC 0.07
- DRTS 0.02
- Stochastic Oscillator
- FULC 71.38
- DRTS 83.51
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
About DRTS Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.